Mesoblast Limited (NASDAQ:MESO) is one of the best low priced biotech stocks to invest in. Mesoblast Limited (NASDAQ:MESO) announced on April 14 that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. The company stated that it plans to employ the engineered CARs to further bolster the effectiveness of the company’s products, aimed at enhancing the target specificity and augmenting the inherent properties of immunomodulation and tissue regeneration.
Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity
Management further stated that the company’s MSC technology platforms, which include the first and only FDA-approved MSC product in the United States, are designed to treat tissue-specific inflammatory diseases because of their inherent homing capabilities and immunomodulatory properties. It added that the primary objective of genetically engineering CAR constructs into MSCs is to considerably enhance targeted homing to inflamed tissue, resulting in greater potency.
Silviu Itescu, Chief Executive of Mesoblast Limited (NASDAQ:MESO), stated that the innovative genetic modification technology fits “well” with the company’s strategy of expanding its market leadership by developing products with increased efficacy and new target indications.
Mesoblast Limited (NASDAQ:MESO) is a biopharmaceutical company involved in the research, development, and marketing of a mesenchymal lineage adult stem cell technology platform. The company’s medicines target cardiovascular diseases, oncology and hematology, spine orthopedic disorders, immune-mediated, and inflammatory diseases.
While we acknowledge the potential of MESO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and…
..
